(NASDAQ: IPA) Immunoprecise Antibodies's forecast annual revenue growth rate of 23.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.77%.
Immunoprecise Antibodies's revenue in 2025 is $16,665,277.On average, 1 Wall Street analysts forecast IPA's revenue for 2026 to be $662,937,882, with the lowest IPA revenue forecast at $662,937,882, and the highest IPA revenue forecast at $662,937,882. On average, 1 Wall Street analysts forecast IPA's revenue for 2027 to be $875,813,872, with the lowest IPA revenue forecast at $875,813,872, and the highest IPA revenue forecast at $875,813,872.
In 2028, IPA is forecast to generate $1,010,832,439 in revenue, with the lowest revenue forecast at $1,010,832,439 and the highest revenue forecast at $1,010,832,439.